<DOC>
	<DOCNO>NCT01850121</DOCNO>
	<brief_summary>The aim study evaluate efficacy infliximab ( IFX ) treatment , 5 mg/kg every 6 week , patient active ankylose spondylitis ( AS ) determine whether IFX dose reduction interval extension , 3 mg/kg every 8 week second year sustain treatment effect . The study start 2003 finished 2008 .</brief_summary>
	<brief_title>Remicade Treatment Patients With Active Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>The patient fulfill follow four inclusion criterion : ( I ) Age 18 60 year , ( II ) proven diagnosis accord modify New York criteria 12 definitive AS , ( III ) active disease Bath AS Disease Activity Index ( BASDAI ) score 4 ( IV ) current previous treatment conventional nonsteroidal antiinflammatory drug ( NSAID ) adequate dos without sufficient effect . current sign symptom severe , progressive uncontrolled hepatic , hematological , pulmonary , cardiac , neurological cerebral disease ; ongoing past serious infection ( include HIV past current tuberculosis ) ; pregnancy breast feeding ; current malignancy history malignancy within past five year ; congestive heart failure contraindication MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>infiximab</keyword>
	<keyword>single arm trial</keyword>
</DOC>